[AMRI] Albany Molecular Research, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 18.58 Change: 0.3 (1.64%)
Ext. hours: Change: 0 (0%)

chart AMRI

Refresh chart

Strongest Trends Summary For AMRI

AMRI is in the long-term up 383% in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. It operates through two segments, Large Scale Manufacturing; and Discovery, Drug Development, and Small-Scale Manufacturing. The company offers drug discovery services, such as assay design and development, screening, screening library, natural products discovery, custom synthesis and library synthesis, medicinal chemistry, computer-aided drug discovery, in vitro ADMET, and bioanalytical services; chemical development services; and chemical synthesis and manufacturing services. It also provides contract manufacturing services in sterile syringe and vial filling for small molecule drug products and biologicals. In addition, the company offers formulation development services for solid dosage, solution, suspension, topicals, and injectables; early clinical phase capsules filling using Xcelodose technology; an

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.6 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 20% Sales Growth - Q/Q-5.52% P/E-13.53
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.58% ROE-3.72% ROI-1.74%
Current Ratio3.53 Quick Ratio2.53 Long Term Debt/Equity1.95 Debt Ratio0.22
Gross Margin24.52% Operating Margin-0.17% Net Profit Margin-3.01% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities41.08 M Cash From Investing Activities-63.47 M Cash From Operating Activities4.37 M Gross Profit23.3 M
Net Profit-2.22 M Operating Profit1.23 M Total Assets571.14 M Total Current Assets189.77 M
Total Current Liabilities53.76 M Total Debt200.91 M Total Liabilities329.27 M Total Revenue81.82 M
Technical Data
High 52 week21.76 Low 52 week13.06 Last close21.74 Last change0%
RSI42.86 Average true range3.13 Beta1.1 Volume139.54 K
Simple moving average 20 days0.02% Simple moving average 50 days0.12% Simple moving average 200 days18.45%
Performance Data
Performance Week-0.05% Performance Month0.18% Performance Quart0.18% Performance Half59.85%
Performance Year46.69% Performance Year-to-date15.88% Volatility daily0.08% Volatility weekly0.17%
Volatility monthly0.35% Volatility yearly1.23% Relative Volume232.3% Average Volume852.92 K
New High New Low

News

2017-10-25 15:00:00 | Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Albany Molecular Research, Inc.

2017-09-12 07:32:00 | 3ST Research Files Litigation Alleging Fraud and Conversion of Inventor's Intellectual Property Rights by Albany Molecular Research Inc. AMRI

2017-08-31 12:30:00 | AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR

2017-08-18 15:45:08 | AMRI shareholders approve sale of company

2017-08-17 17:47:00 | Control4 Set to Join S&P SmallCap 600

2017-07-19 11:29:09 | Albany Molecular Research, Inc. -- Moody's assigns B3 CFR to UIC Merger Sub, Inc. dba Albany Molecular Research, Inc.

2017-07-17 09:00:00 | The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Albany Molecular Research, Inc. – AMRI

2017-07-13 15:29:00 | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. AMRI

2017-07-05 16:51:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Albany Molecular Research, Inc. - AMRI

2017-07-03 16:55:00 | Lifshitz & Miller LLP Announces Investigation of Albany Molecular Research, Inc., Atwood Oceanics, Inc., CardConnect Corp., Covisint Corporation, Sajan, Inc., Whole Foods Market, Inc. and Xactly Corporation

2017-06-29 08:00:00 | AMRI Announces Early Termination of HSR Waiting Period for The Carlyle Group and GTCR's Proposed Acquisition of AMRI

2017-06-20 14:34:00 | EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Albany Molecular Research, Inc. to The Carlyle Group and GTCR LLC is Fair to Shareholders - AMRI

2017-06-15 17:35:00 | SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research, Inc -AMRI

2017-06-13 18:11:00 | INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Albany Molecular Research, Inc. and Encourages Investors to Contact the Firm for Additional Information

2017-06-13 14:29:00 | The Law Offices of Vincent Wong Reminds Investors of an Investigation of Albany Molecular Research, Inc. in Connection with the Sale of the Company to GTCR LLC and The Carlyle Group

2017-06-09 15:12:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research, Inc - AMRI

2017-06-09 15:05:00 | The Law Offices of Vincent Wong Notifies Investors of an Investigation of Albany Molecular Research, Inc. in Connection with the Sale of the Company to GTCR LLC and The Carlyle Group

2017-06-09 13:42:00 | WeissLaw LLP: The Proposed Acquisition of Albany Molecular Research Inc. May Not Be In the Best Interest of AMRI Shareholders

2017-06-08 13:23:17 | ETFs with exposure to Albany Molecular Research, Inc. : June 8, 2017

2017-06-07 17:26:00 | Harwood Feffer LLP Announces Investigation of Albany Molecular Research, Inc.

2017-06-07 15:21:00 | SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Albany Molecular Research, Inc. and Encourages Investors to Contact the Firm for Additional Information

2017-06-07 14:36:00 | INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Albany Molecular Research, Inc. to The Carlyle Group and GTCR LLC is Fair to Shareholders

2017-06-07 12:28:00 | Albany Molecular Research, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Merger with The Carlyle Group

2017-06-07 12:16:06 | Albany Molecular Research, Inc. -- Moody's places Albany Molecular's ratings on review for downgrade

2017-06-06 22:30:00 | ALBANY MOLECULAR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albany Molecular Research, Inc.

2017-06-06 19:47:00 | SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research, Inc -AMRI

2017-06-06 17:50:30 | HD Supply and Casey's General Stores fall; G-III leaps

2017-06-06 15:57:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Albany Molecular Research, Inc. to The Carlyle Group and GTCR LLC is Fair to Shareholders

2017-06-06 13:39:07 | GTCR, Carlyle to buy contract research firm Albany Molecular

2017-06-06 12:19:00 | ALBANY MOLECULAR RESEARCH, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

2017-06-06 10:36:31 | [$$] Carlyle, GTCR to Acquire Contract-Drug Manufacturer

2017-06-06 09:50:38 | Why Albany Molecular Is Actually Getting a Very Good Premium

2017-06-06 09:31:00 | Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

2017-06-06 09:11:36 | Albany Molecular Research, Inc. :AMRI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017

2017-06-06 08:48:00 | Albany Molecular AMRI Alert: J&W Investigates Price and Process of Proposed Sale of Albany Molecular Research, Inc.; Is $21.75 a Fair Price?

2017-06-06 07:55:08 | Equity firms in talks to acquire this public company in Albany

2017-06-06 07:38:00 | Albany Molecular Research to be taken private for $21.75 a share in cash

2017-06-06 07:30:00 | AMRI Signs Definitive Agreement To Be Acquired By The Carlyle Group and GTCR for $21.75 per share in cash

2017-06-02 09:15:00 | AMRI to Present at Jefferies Healthcare Conference

2017-05-13 11:08:04 | Edited Transcript of AMRI earnings conference call or presentation 9-May-17 12:30pm GMT

2017-05-10 08:51:02 | Edited Transcript of AMRI earnings conference call or presentation 9-May-17 12:30pm GMT

2017-05-09 08:31:24 | Albany Molecular Research posts 1Q loss

2017-05-09 07:45:00 | Investor Network: Albany Molecular Research, Inc. to Host Earnings Call

2017-05-09 07:30:00 | AMRI Announces First Quarter 2017 Results

2017-05-02 08:00:00 | AMRI Receives NIH Contract Award for Drug Substance Development and Manufacturing Services

2017-04-26 16:06:25 | Report: AMRI considering $1 billion sale

2017-04-26 08:00:00 | SSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing

2017-04-25 08:00:00 | AMRI Schedules First Quarter 2017 Earnings Release and Conference Call

2017-04-24 07:00:00 | Denovo Biopharma Obtains Exclusive License To Liafensine From AMRI

2017-04-07 15:46:21 | ETFs with exposure to Albany Molecular Research, Inc. : April 7, 2017